Seminal
The magazine and atlas of EU-funded researchA new publication from the web and AI team at Scott Charnley

Atlas / Norway

Innovation Action · Running

BioFACTORy Fully automated cell and tissue-engineered bioimplant production for orocraniofacial regeneration

Coordinator
Universitetet I Bergen, Norway
Runs
1 September 2026 to 31 August 2030
Status
Running
EU funding
€8.1m
Total cost
—
Partners
14 organisations in 9 countries
Type
Innovation Action
Grant agreement
101286740

What the project is doing

In the project's own words, from its summary on CORDIS.

Craniofacial defects caused by cancer resection, infection, or trauma significantly impair patients’ quality of life by affecting facial aesthetics and masticatory function. While autologous bone grafting remains the clinical standard, it requires secondary surgery, leads to donor site morbidity and prolonged hospitalisation. Europe has pioneered MSC (mesenchymal stem/stromal cell)-based regenerative therapies as alternatives, with our consortium leading key Phase I–IIB trials (FP7 REBORNE, H2020 MAXIBONE).

Despite this progress, broader clinical adoption is hindered by high treatment costs and challenges in standardising cell manufacturing. For example, current GMP-compliant production of autologous BMSCs exceeds €30,000 per patient. Commercial GMP-compliant bioreactors (e.g., Quantum®) have improved scalability, but costs remain high due to consumables and maintenance. BioFACTORy addresses these limitations by developing GMP-conform automated platform powered by trustworthy AI tools (AI Biologist) to optimise the manufacturing of MSC-based tissue engineered medicinal products (TEMP).

The system will improve standardisation and scalability while reducing production cost by optimising all steps from cell isolation and expansion to quality control. The project will also address the batch-to-batch/donor-to-donor inconsistency and resulting therapeutic uncertainty by implementing quality-by-design principles in MSC manufacturing, namely development of critical quality attributes (CQAs) and MSC licensing strategies.

In parallel, the consortium will engage with EU regulators to develop regulatory roadmaps, ensuring clinical readiness. With expertises in GMP cell production, cell therapy, AI and lab automation in the consortium, BioFACTORy will lay the groundwork for scalable, cost-effective, and reproducible production of TEMPs, positioning Europe as a leader in personalised regenerative medicine, with a focus on orocraniofacial reconstruction.

Topics

Who is involved

OrganisationCityCountryRole
Universitetet I BergenBergenNorwayCoordinator
Novasign GmbHViennaAustriaParticipant
Fraunhofer Gesellschaft Zur Forderung Der Angewandten Forschung eVMunchenGermanyParticipant
Presens Precision Sensing GmbHRegensburgGermanyParticipant
Technische Hochschule Wuerzburg-SchweinfurtWurzburgGermanyParticipant
Universitaet UlmUlmGermanyParticipant
Universidad Complutense De MadridMadridSpainParticipant
Universitat De BarcelonaBarcelonaSpainParticipant
F6s EU Tech Innovation Network DacDublinIrelandParticipant
Istituto Di Ricerche Farmacologiche Mario NegriMilanoItalyParticipant
Ocean TuniCell ASBlomsterdalenNorwayParticipant
Politechnika SlaskaGliwicePolandParticipant
Cellink Bioprinting ABGoteborgSwedenParticipant
King's College LondonLondonUnited KingdomParticipant

Source: CORDIS, European Commission. Data of 5 Nov 2026, reused under the Commission's reuse policy. View on CORDIS · Grant DOI